American International Group Inc. raised its stake in shares of Supernus Pharmaceuticals Inc (NASDAQ:SUPN) by 5.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 37,920 shares of the specialty pharmaceutical company’s stock after purchasing an additional 2,070 shares during the period. American International Group Inc. owned 0.07% of Supernus Pharmaceuticals worth $1,517,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of SUPN. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Supernus Pharmaceuticals by 278.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,018 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 2,220 shares during the period. Riverhead Capital Management LLC grew its stake in Supernus Pharmaceuticals by 91.4% during the second quarter. Riverhead Capital Management LLC now owns 3,062 shares of the specialty pharmaceutical company’s stock worth $132,000 after buying an additional 1,462 shares during the period. Advisor Group Inc. grew its stake in Supernus Pharmaceuticals by 13.7% during the second quarter. Advisor Group Inc. now owns 3,395 shares of the specialty pharmaceutical company’s stock worth $145,000 after buying an additional 410 shares during the period. Victory Capital Management Inc. grew its stake in Supernus Pharmaceuticals by 17.7% during the second quarter. Victory Capital Management Inc. now owns 3,441 shares of the specialty pharmaceutical company’s stock worth $148,000 after buying an additional 517 shares during the period. Finally, Flinton Capital Management LLC grew its stake in Supernus Pharmaceuticals by 88.9% during the second quarter. Flinton Capital Management LLC now owns 4,760 shares of the specialty pharmaceutical company’s stock worth $205,000 after buying an additional 2,240 shares during the period. 98.34% of the stock is owned by hedge funds and other institutional investors.

Several research firms have issued reports on SUPN. Janney Montgomery Scott upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a research note on Monday, December 4th. ValuEngine downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. B. Riley restated a “buy” rating and issued a $50.00 target price on shares of Supernus Pharmaceuticals in a research note on Monday, November 20th. Zacks Investment Research downgraded shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 10th. Finally, Stifel Nicolaus upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 target price for the company in a research note on Tuesday, November 7th. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Supernus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $49.60.

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) opened at $38.60 on Friday. The firm has a market cap of $1,955.65, a price-to-earnings ratio of 35.99, a PEG ratio of 1.61 and a beta of 1.19. Supernus Pharmaceuticals Inc has a 52 week low of $22.70 and a 52 week high of $50.04.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.02. The business had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. Supernus Pharmaceuticals’s revenue for the quarter was up 41.5% compared to the same quarter last year. analysts forecast that Supernus Pharmaceuticals Inc will post 1.07 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/supernus-pharmaceuticals-inc-supn-shares-bought-by-american-international-group-inc/1765057.html.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.